OUR COMMITMENTS TO PAEDIATRIC HIV: RESEARCH PARTNERS SHARE NEW DOLUTEGRAVIR DATA ON TREATMENT OF HIV-INFECTED CHILDREN
London, UK, 14 March 2019 - Last week at CROI 2019 in Seattle, our clinical trial partners from IMPAACT and PENTA networks presented new clinical data on paediatric dolutegravir from the P1093 and ODYSSEY studies:
- PK and 4 week outcomes of dolutegravir dispersible tablets in HIV-infected children (IMPAACT, P1093 study)
- Adult DTG 50mg film-coated tablets in children living with HIV weighing 20 - <25kg (PENTA, ODYSSEY PK sub-study)
These new data provide more needed information and bring the joint IMPAACT-PENTA-ViiV Healthcare team a step closer to achieving our target to deliver on our commitment towards the FDA & EU regulatory submissions.
Further data is needed for the regulatory dossiers to meet on stringent regulatory authority expectations. This continues to be a key priority for ViiV Healthcare and the IMPAACT and PENTA networks through 2019. We will continue to update our partners and the community as we progress towards our goal.